NYMX Nymox Pharmaceutical Corporation

3.85
+0.09  (2%)
Previous Close 3.76
Open 3.80
Price To book 22741.23
Market Cap 209448262
Shares 54,402,146
Volume 4,409
Short Ratio 15.37
Av. Daily Volume 91,391

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Data released February 2016 met endpoint
NX-1207 long-term NX03-0040 trial
Low grade localized prostate cancer
Phase 3 endpoints met in extension trial July 2015. Noted March 28, 2017 that regulatory filing is due during the next few weeks.
NX-1207 Fexapotide
BPH

Latest News

  1. Nymox Fexapotide Symposium and Panel Discussion at American Urological Association North Central Sectional Annual Meeting in Scottsdale
  2. Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association North Central Section Annual Meeting in Scottsdale AZ November 15
  3. Nymox Reports on Symposium, Panel Discussion and Podium Presentation on Fexapotide at American Urological Association New York Section Annual Meeting in Havana
  4. Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio?
  5. Nymox Announces Two Data Presentations for Company's BPH Drug at New York American Urological Association Meeting November 6
  6. Nymox Reports on Symposium, Panel Discussion with Abstract on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah
  7. Nymox Reports on Symposium and Panel Discussion on Fexapotide at American Urological Association Northeast Sectional Annual Meeting in Savannah October 12
  8. Nymox Announces October 12 Symposium for Company's BPH Drug at American Urological Association Meeting
  9. Nymox Application Validated:
  10. Nymox Announces New Symposium for Company's BPH Drug at American Urological Association Meeting October 5
  11. ETFs with exposure to Nymox Pharmaceutical Corp. : September 12, 2017
  12. AUA Meeting in Florida September 16 Postponed Due to Hurricane
  13. ETFs with exposure to Nymox Pharmaceutical Corp. : August 31, 2017
  14. Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  15. ETFs with exposure to Nymox Pharmaceutical Corp. : July 4, 2017
  16. Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017